Skip to main content

Table 7 Safety outcomes: OHSS

From: In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

Characteristic

Total

rFSH

hMG-hp

Chi-square

p-value

Number of cycles started*

28063

20144

7919

  

Cycles with OHSS (Severity I, II, III and hospitalisation)

4928 (17.56%)

3812 (18.92%)

1116 (14.09%)

91.64

<0.0001

-Hospitalisation due to OHSS as percent of cycles with OHSS

268 (5.44%)

215 (5.64% of cycles with OHSS)

53 (4.75% of cycles with OHSS)

1.33

0.2483

-Hospitalisation due to OHSS as percent of cycles started

268 (0.95%)

215 (1.07% of cycles started)

53 (0.67% of cycles started)

9.52

0.002

  1. *Due to lack of data on this outcome only data from Germany were included